A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2004
12/09/2004	US20040247613 A nucleic acid expression vector encodes the catalytic subunit of human telomerase reverse transcriptase (hTRT); immunostimulants; anticarcinogenic agents; gene therapy
12/09/2004	US20040247612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease
12/09/2004	US20040247611 Immunoassay for identifying pathogen-ligand interactions under shear conditions; vaccines containing an anti-adhesive monoclonal antibody, an adhesive peptide, or a pathogen adhesin
12/09/2004	US20040247610 A lysine-glycine-lysine-glycine-Xaa pentapeptide residue complexed with one or more B-cell or T-cell determinants and targeting molecules; influenza type A vaccinations
12/09/2004	US20040247609 Administering a non-specific immunopotentiator before administering an antigen protein ; particularly administering a cancer antigen protein, WT1, or a peptide derived from the WT1 protein in combination with a bacterium-derived component or IFN-alpha
12/09/2004	US20040247608 The hapten moieties are attached, directly or indirectly, to lysines of the monomeric units of the carrier; particularly an aggregated STn-KLH conjugate; used particularly for cancer immunotherapy
12/09/2004	US20040247607 Use of surfactants to stabilize oocysts
12/09/2004	US20040247606 Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
12/09/2004	US20040247605 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
12/09/2004	US20040247604 Anti-inflamatory fatty alcohols and fatty acid esters useful as antigen carriers
12/09/2004	US20040247602 Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds
12/09/2004	US20040247599 Modulators of the P2Y10 receptor useful in altering T lymphocyte function
12/09/2004	US20040247598 In particular of delayed-type hypersensitivity; especially administering an IL-18 binding protein or a derivative, an expression vector or a genetically engineered cell, optionally with an antiinflammatory agent such as a COX-inhibitor.
12/09/2004	US20040247597 Method of treating atherosclerosis and other inflammatory diseases
12/09/2004	US20040247591 administering a humanized or chimeric antibody that specifically binds to an epitope within A beta 3-6, A; used for treating Alzheimer's disease in both asymptomatic patients and those currently showing symptoms of disease.
12/09/2004	US20040247590 Prevention and treatment of amyloidogenic disease
12/09/2004	US20040247588 Lyophilizing a solution of a modified antibody (especially Certolizumab Pegol) containing molecules capable of adversely affecting the stability or solubility of the antibody after lyophilization and from which some of those moledules have been removed
12/09/2004	US20040247579 Mixed chimerism and tolerance
12/09/2004	US20040247578 Administering into or near a site of a tumor or infectious lesion an antigen presenting cell, especially a dendritic cell, and an immunostimulatory cytokine or a nucleic acid encoding an immunostimulatory cytokine
12/09/2004	US20040247564 Treating a tissue disorder involving a loss and/or apoptosis of cells by administering an agent that induces phosphorylation and/or activation of protein kinase B to cause proliferation; particularly administering a human stromal-derived factor-1 and a G-CSF to cause proliferation of cardiomyocytes
12/09/2004	US20040247554 Compositions and method for promoting the growth of human hair
12/09/2004	CA2527795A1 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
12/09/2004	CA2527722A1 Biodegradable poly(beta-amino esters) and uses thereof
12/09/2004	CA2526883A1 A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor .alpha.
12/09/2004	CA2526623A1 Soluble clca-1 and antagonists to clca-1
12/09/2004	CA2525717A1 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
12/09/2004	CA2525540A1 Enterococcus antigens
12/09/2004	CA2523716A1 Human anti-human cd3 binding molecules
12/09/2004	CA2495270A1 Transdermal vaccine delivery device having coated microprotrusions
12/08/2004	EP1484405A1 Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis
12/08/2004	EP1484404A1 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
12/08/2004	EP1484402A2 Antibody for use in therapy
12/08/2004	EP1484400A1 Sodium-independent transporter carrying acidic amino acid and its gene
12/08/2004	EP1484397A1 Peptide from antigen MUC-1 for triggering an immune response to tumor cells
12/08/2004	EP1484391A1 Vaccine against mumps
12/08/2004	EP1484340A1 Antibodies to a novel mammalian protein associated with uncontrolled cell division
12/08/2004	EP1484336A1 Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
12/08/2004	EP1484064A1 Therapeutical composition containing dentritic cells and use thereof
12/08/2004	EP1484063A2 Method for inhibiting rejection of transplanted tissue
12/08/2004	EP1483575A2 Methods for isolating ligands e.g. t cell epitopes
12/08/2004	EP1483389A2 Genetic products differentially expressed in tumors and use thereof
12/08/2004	EP1483385A2 Compositions and methods for generating an immune response
12/08/2004	EP1483374A2 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vivo
12/08/2004	EP1483372A2 Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions
12/08/2004	EP1483297A2 Antibodies derived from anti ed-b l19 and targeting tumor vasculature
12/08/2004	EP1483296A1 Specific ab1'-antibodies against tumour-associated antigen ca 125
12/08/2004	EP1483292A1 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
12/08/2004	EP1483289A2 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
12/08/2004	EP1483288A2 Hbm variants that modulate bone mass and lipid levels
12/08/2004	EP1483287A1 An infectious bursal disease virus variant
12/08/2004	EP1482984A2 Surrogate antibodies and methods of preparation and use thereof
12/08/2004	EP1482983A2 Non-myeloablative tolerogenic treatment with tyrphostins
12/08/2004	EP1482981A1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
12/08/2004	EP1482973A1 Methods of modulating cd200 receptors
12/08/2004	EP1482972A2 Treatment of immunological disorders using anti-cd30 antibodies
12/08/2004	EP1482971A1 Strategy for retroviral immunotherapy
12/08/2004	EP1482970A1 Cancer therapy
12/08/2004	EP1482963A2 Controlled modulation of amino acid side chain length of peptide antigens
12/08/2004	EP1482795A1 New immunoeffector compounds
12/08/2004	EP1326960B1 Microbes having an attenuating mutation comprising a transcription terminator
12/08/2004	EP0966535B1 Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides
12/08/2004	EP0824548B1 Hybrid molecules between heat-labile enterotoxin and cholera toxin b subunits
12/08/2004	CN1554026A Prognostic indicator
12/08/2004	CN1553961A Membrane virus host range mutations and their uses as vaccine substrates
12/08/2004	CN1553958A Photochemical internalization for delivery of molecules into the cytosol
12/08/2004	CN1553813A Complement pathway inhibitors binding to C5 and C5A without preventing formation of C5B
12/08/2004	CN1553812A 自体t-细胞疫苗材料和方法 Autologous vaccines Materials and Methods Cell t-
12/08/2004	CN1553806A Use of SAPR-1 for the treatment and/or prevention of scleroderma
12/08/2004	CN1553803A Use of 4-pyridylmethylphthalazines for cancer treatment
12/08/2004	CN1552856A DNA encoding a plasminogen-activating protein
12/08/2004	CN1552855A Vascular endothelial growth factor 2
12/08/2004	CN1552736A Monoclone antibody against HnRNP A2/B1 antigen, its preparation and use
12/08/2004	CN1552735A Engineering antibody against CD44 for inducing leukemia cell differentation and necrosis
12/08/2004	CN1552447A Adjuvant for improving hepatitis B vaccine immune effect and preparing method thereof
12/08/2004	CN1552446A Nucleic acid vaccin for preventing and treating hepatitis B virus inflammation and its preparation
12/08/2004	CN1552445A Medicinal preparation for preventing from pyloric helicobacterium inflammation
12/08/2004	CN1179048C Modified MSP-1 nucleic acid sequences and method for increasing mRN-A level and protein expression in cell system
12/08/2004	CN1178956C Cancer antigens based on tumor suppressor gene WT1 product
12/08/2004	CN1178955C Modified TNF alpha molecules and DNA encoding such modified TNF alpha molecules and vaccines comprising such modified TNF alpha molecules and DNA
12/08/2004	CN1178950C Corpuscles of stannius protein and stanniocalcin
12/08/2004	CN1178698C Attenuated pig genital and respiratory syndrome virus and its using method
12/08/2004	CN1178697C Infectious bursits vaccine
12/08/2004	CN1178671C Egg anti-inflammatory composition and isolation method and use
12/07/2004	US6828431 Compositions and methods for the therapy and diagnosis of breast cancer
12/07/2004	US6828424 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of arthritis and cancer; for use as antiscarring agent
12/07/2004	US6828416 Recombinant multivalent malarial vaccine against Plasmodium falciparum
12/07/2004	US6827939 Amino acid sequences for use in detection and treatment of viral infection
12/07/2004	US6827937 HBV capsid-binding peptide immunogens
12/07/2004	US6827936 Glucosyltransferase subunits; radially branched macromolecular structure with peptidyl core matrix comprised of at least lysine, arginine and histidine
12/07/2004	US6827935 Method of and compositions for immunization with the pseudomonas V antigen
12/07/2004	US6827934 Autoimmune and infectious diseases, transplant rejection, inflammatory disorders; reduced immunogenicity
12/07/2004	US6827925 Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof
12/07/2004	CA2217776C Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
12/07/2004	CA2208673C Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
12/02/2004	WO2004104189A1 New enterovirus, vaccines, medicaments and diagnostic kits
12/02/2004	WO2004104182A1 Bioactive peptide-producing strains of enterococcus faecalis, bioactive peptides and applications thereof
12/02/2004	WO2004104047A1 Hypoallergenic variants of the parietaria judaica major allergens, uses thereof and compostitions comprising them
12/02/2004	WO2004104039A2 Tumor antigens for prevention and/or treatment of cancer
12/02/2004	WO2004104033A2 Viruses dependent on inducing agents for viral entry into a host cell
12/02/2004	WO2004104031A2 Modified antiviral peptides with increased activity and cell membrane affinity

1 ... 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 ... 1823